Cooper Companies Inc (NYSE:COO) – Investment analysts at KeyCorp decreased their Q2 2018 earnings estimates for shares of Cooper Companies in a report issued on Sunday. KeyCorp analyst M. Mishan now forecasts that the medical device company will earn $2.84 per share for the quarter, down from their prior estimate of $3.03. KeyCorp also issued estimates for Cooper Companies’ FY2018 earnings at $11.81 EPS and FY2019 earnings at $12.73 EPS.
Cooper Companies (NYSE:COO) last posted its earnings results on Thursday, March 8th. The medical device company reported $2.79 EPS for the quarter, topping the Zacks’ consensus estimate of $2.51 by $0.28. Cooper Companies had a return on equity of 16.90% and a net margin of 7.83%. The business had revenue of $590.00 million during the quarter, compared to analyst estimates of $583.07 million. During the same quarter last year, the company earned $1.93 EPS. The company’s quarterly revenue was up 18.2% compared to the same quarter last year.
Shares of Cooper Companies (NYSE COO) opened at $240.95 on Tuesday. The company has a quick ratio of 1.61, a current ratio of 2.83 and a debt-to-equity ratio of 0.75. Cooper Companies has a fifty-two week low of $192.24 and a fifty-two week high of $260.26. The company has a market capitalization of $12,325.45, a price-to-earnings ratio of 69.04, a P/E/G ratio of 1.98 and a beta of 0.61.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in COO. BB&T Investment Services Inc. lifted its position in Cooper Companies by 71.0% during the fourth quarter. BB&T Investment Services Inc. now owns 542 shares of the medical device company’s stock valued at $119,000 after purchasing an additional 225 shares in the last quarter. Canada Pension Plan Investment Board purchased a new position in Cooper Companies during the third quarter valued at $163,000. Virtue Capital Management LLC purchased a new position in Cooper Companies during the fourth quarter valued at $195,000. FNY Managed Accounts LLC purchased a new position in Cooper Companies during the fourth quarter valued at $217,000. Finally, CAPROCK Group Inc. purchased a new position in Cooper Companies during the fourth quarter valued at $222,000. Institutional investors own 98.55% of the company’s stock.
In related news, CEO Robert S. Weiss sold 32,500 shares of Cooper Companies stock in a transaction on Monday, December 18th. The stock was sold at an average price of $224.70, for a total transaction of $7,302,750.00. Following the transaction, the chief executive officer now directly owns 119,111 shares in the company, valued at $26,764,241.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director A Thomas Bender sold 9,150 shares of Cooper Companies stock in a transaction on Monday, December 18th. The shares were sold at an average price of $229.17, for a total value of $2,096,905.50. Following the transaction, the director now owns 11,205 shares in the company, valued at $2,567,849.85. The disclosure for this sale can be found here. Insiders have sold 54,385 shares of company stock worth $12,289,463 over the last quarter. 1.60% of the stock is owned by company insiders.
Cooper Companies Company Profile
The Cooper Companies, Inc is a global medical device company. The Company operates through two business units: CooperVision, Inc and CooperSurgical, Inc CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses.
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.